Allspring Global Investments Holdings LLC Decreases Holdings in DaVita Inc. (NYSE:DVA)

Allspring Global Investments Holdings LLC cut its holdings in shares of DaVita Inc. (NYSE:DVAGet Rating) by 17.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,791 shares of the company’s stock after selling 1,465 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in DaVita were worth $562,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DVA. Raymond James & Associates increased its holdings in DaVita by 4.0% in the 1st quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock worth $2,562,000 after acquiring an additional 865 shares during the last quarter. American Century Companies Inc. increased its holdings in DaVita by 37.4% in the 1st quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock worth $741,000 after acquiring an additional 1,785 shares during the last quarter. US Bancorp DE increased its holdings in DaVita by 63.6% in the 1st quarter. US Bancorp DE now owns 2,998 shares of the company’s stock worth $338,000 after acquiring an additional 1,166 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in DaVita by 7.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock worth $402,000 after acquiring an additional 242 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its holdings in DaVita by 847.8% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock worth $123,000 after acquiring an additional 975 shares during the last quarter. 86.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the subject of several recent research reports. UBS Group lowered DaVita from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $117.00 to $74.00 in a report on Monday, October 31st. Barclays cut their target price on DaVita from $103.00 to $81.00 and set an “equal weight” rating for the company in a research note on Monday, October 31st. Truist Financial cut their target price on DaVita from $90.00 to $75.00 and set a “hold” rating for the company in a research note on Monday, October 31st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Friday, December 9th. Finally, TheStreet downgraded DaVita from a “b-” rating to a “c+” rating in a research note on Tuesday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $81.17.

Insider Activity

In other DaVita news, Director John M. Nehra purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, November 1st. The stock was purchased at an average price of $71.14 per share, for a total transaction of $355,700.00. Following the transaction, the director now owns 15,000 shares in the company, valued at approximately $1,067,100. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.

DaVita Stock Performance

Shares of DVA opened at $80.10 on Tuesday. The company has a market cap of $7.22 billion, a PE ratio of 11.73, a price-to-earnings-growth ratio of 1.47 and a beta of 0.96. The company has a current ratio of 1.26, a quick ratio of 1.22 and a debt-to-equity ratio of 12.63. The stock has a 50-day moving average price of $74.81 and a 200-day moving average price of $82.18. DaVita Inc. has a 12-month low of $65.28 and a 12-month high of $124.81.

DaVita (NYSE:DVAGet Rating) last issued its quarterly earnings results on Friday, October 28th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.20). The business had revenue of $2.95 billion for the quarter, compared to the consensus estimate of $2.98 billion. DaVita had a net margin of 5.84% and a return on equity of 85.60%. The business’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the business posted $2.36 EPS. As a group, equities analysts forecast that DaVita Inc. will post 6.32 earnings per share for the current fiscal year.

DaVita Profile

(Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVAGet Rating).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.